An observational study in Diabetic Retinopathy, sponsored by Association for Innovation and Biomedical Research on Light and Image. Completed at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image — 2 open to participants now, 3 under way, none of them phase 3. Diabetic Retinopathy · Association for Innovation and Biomedical Research on Light and Image.
Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, this one is the 12th largest by enrollment of the 16 observational ones that give a count, is one of 2 that started in 2022, is one of 16 observational ones, and was the 13th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image are open now, in 1 country. Recruiting first, the newest first:
Association for Innovation and Biomedical Research on Light and Image · Sites in Portugal
Ages 35–80
Association for Innovation and Biomedical Research on Light and Image · Sites in Portugal
Ages 35–90
By country, each count listing its studies:
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2022.
This study's enrollment of 60 is below the median of 173 across 265 observational studies indexed under Diabetic Retinopathy.
Median enrollment 84 across the 2 interventional studies, 81 across the 16 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Association for Innovation and Biomedical Research on Light and Image is the lead sponsor of 38 studies on the registry; 5 are open to participants now.
2 of the studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07417410Association for Innovation and Biomedical Research on Light and ImageAnalysis of DR Progression to Identify Risks and Need for Treatment | 2026-11 |
| NCT07458516Association for Innovation and Biomedical Research on Light and ImageLongitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Retinal ischemia characterization in diabetes - RICHARD
RICHARD is a non-interventional observational cross-sectional and prospective study. Patients will attend their routine clinical appointments, with 2-years of follow-up. Type 2 diabetic individuals with retinopathy ETDRS DRSS grade 43 with IRMA or grade 47-53 will be recruited and examined using non-invasive methodologies.
The study will be performed at AIBILI Clinical Trials Centre (CEC). Demographic and systemic parameters, such as diabetes duration, medical history, medication, body mass index, and family history of medical conditions (particularly when related to cognitive decline) will be registered at baseline.
All subjects will undergo an annual complete non-invasive ophthalmological examination, which includes, best corrected visual acuity, 7-fields CFP to assess ETDRS DRSS level, structural SD-OCT, SD-OCTA, SS-OCTA and ultra-widefield fundus photography (UWF FP). An invasive ophthalmological examination, the Ultra-wide field fundus fluorescein angiography (UWF FFA) will be obtained from both eyes at baseline (V0, M0) only in subjects with ETDRS DRSS grade 43 for final eligibility (43+IRMA).
Ophthalmological examinations performed will be analyzed at AIBILI Coimbra Ophthalmology Reading Centre (CORC) and Centre for New Technologies e Medicine (CNTM).
Color fundus photography (7-fields) will be acquired at V0 (month 0, baseline, cross-sectional study), V2 (month 12) and V3 (month 24), and then graded and classified according to the ETDRS severity scale by CORC, to allow evaluation of retinopathy progression over two years of follow-up. . At baseline visit (V0) both eyes will be evaluated and the study eye will be selected according to ETDRS DRSS grade (43 with IRMA, 47 or 53). Only the study eye will be considered for the primary statistical analysis; other statistical analyses will include both eyes.
60 individuals with type 2 diabetes and diabetic retinopathy with ETDRS DRSS grade 43 with IRMA, 47 or 53, with or without previous treatment, will be included in this study, over a recruitment period of 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OCTA metrics and predict progression to PDR and/ or CI- DME
Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.
Time frame: Change from baseline to Month 12
OCTA metrics and predict progression to PDR and/ or CI- DME
Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.
Time frame: Change from baseline to Month 24
Ran from Mar 2022 to primary completion in Apr 2025, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association for Innovation and Biomedical Research on Light and Image